• Skip to Management
  • Skip to Main menu
  • Skip to Page content
Adlershof Logo
  • WISTA
  • WISTA.Plan
  • WISTA.Service
WISTA direkt
Search
  • de
  • en
  • Adlershof Logo
  • About / Directory
    • Companies / Institutes
    • Science City in numbers
    • Direction / Maps
      • Bus / Train
      • By Car
      • Bicycle
      • Orientation / Maps
      • Trail of Thoughts
  • Newsroom
    • Overview
    • News
      • Social Media Stream
      • Success Stories
    • Events / Calendar
      • Adlershof Dissertation Award
      • Adlershof Research Forum
      • Long Night of Sciences Berlin
    • Adlershof Journal
    • Hot Topics
      • Adlershof Mission "Grand Challenges"
      • Circular Economy
      • Digital infra­structure / 5G campus network
    • Photos / Flyer / Downloads
      • Magazine archive
    • WISTA-Editorial Staff
  • Science / Technology
    • Overview
    • Technology Centres
      • Photonics / Optics
      • Biotech­nology / Envi­ron­ment
      • Micro­systems / Materi­als
      • IT / Media
      • Renewable Energy / Photovoltaics
    • Non-university Research
    • Universities / Colleges
      • Humboldt-Universität zu Berlin
      • Services for Students
    • Young Talents / STEM / School Labs
    • Start-Ups
      • Adlershof Start-Up Centre IGZ
      • Adlershof Founder’s Lab
    • Networks / Management
      • Campus Club Adlershof
  • TV / Media
    • TV and Movie Production
    • Media Services / Companies
    • News and Events
    • Filming Locations
    • Costume Hire
    • GDR Film Archive
    • Tickets / Booking
  • Properties
    • Overview
    • Real Estate Rent
      • Office Space / Workspace / Laboratories
    • Real Estate Offers
      • Commercial Properties
    • ST3AM Working Environments / Coworking
    • Residential
    • Construction
      • Building Projects
      • Architecture
      • Webcam
  • Service
    • Overview
    • Gastronomy / Sport / Culture / Shopping
    • Jobs / Market
    • Social and Healthcare Facilities
    • WISTA-Business Services
    • Event Services / Guided Tours / Hotels
    • Facility Management
    • Downloads / Photos / Videos
    • Jobs for Refugees
  • Hood
    • Overview
    • History
    • Nature Park
    • Culture
    • Technology Park
    • Digital Tours
  • WISTA
  • WISTA.Plan
  • WISTA.Service
WISTA direkt

News

  • Overview
  • News
  • Events / Calendar
  • Adlershof Journal
  • Hot Topics
  • Photos / Flyer / Downloads
  • WISTA-Editorial Staff
  • Adlershof
  • Newsroom
  • News
25. March 2020

MagForce AG announces plans for further NanoTherm Treatment Centre

Therapy for brain tumour patients will also be available in Thuringia

MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, and the Hufeland Klinikum GmbH, announced the conclusion of a joint cooperation agreement and the planned opening of a NanoTherm treatment center for brain tumors at the Mühlhausen site in Thuringia, Germany.

The new treatment center is managed by Privatdozent (PD) Dr. Johannes Wölfer, head physician of the Department of Neurosurgery and Spinal Surgery. As a long-standing expert in the use of MagForce's NanoTherm Therapy System, PD Dr. Wölfer was involved in the development of the training concept for the ‘NanoTherm Therapy School’, among other things. Through ‘NanoTherm Therapy School’, surgeons are certified in the use of the innovative technology by participating in a comprehensive series of application training courses. Before joining the Hufeland Klinikum in 2017, PD Dr. Wölfer was deputy director of the Department of Neuro-oncology at the Münster University Hospital (UKM), which has treated brain tumor patients with the NanoTherm Therapy System since the beginning of 2015. As a member of the UKM team, PD Dr. Wölfer successfully used a new application method for nanoparticles, "NanoPaste", for the first time in 2016. In clinical studies, the team was able to show that the outcome of thermotherapy for tumor ablation can be significantly enhanced if the heat-generating nanoparticles are better applied around the edge of the resection that occurs after the brain tumor has been removed. For its research, the team was awarded the "Best Abstract Award" of the EANS congress, among others. PD Dr. Wölfer also plans to offer state-of-the-art brain tumor therapy at the Hufeland Klinikum in Mühlhausen with the NanoTherm Therapy System.

"The Hufeland Klinikum GmbH in Mühlhausen offers excellent conditions for our work, has very modern technical equipment and is also excellently well positioned in terms of personnel. The vision of our neurological faculties is to use the potential of the NanoTherm Therapy System and create a lighthouse in the region for the treatment of brain tumors," said Chief Physician PD Dr. Johannes Wölfer. "For many gliomas, surgery, i.e. the removal of the tumor as far as possible, is top priority. If the tumor returns despite all treatments, in 90 percent of cases this happens at the edges of the former operation. With the help of heat, additional tumor tissue can be destroyed here. However, healthy brain tissue does not tolerate heat well. The medical challenge was therefore to generate the heat in such a way that as little healthy tissue as possible is damaged. This is where nanotechnology comes in, opening up new treatment options for us."

The Hufeland Klinikum at the Mühlhausen site in Thuringia will be the fourth clinic in Europe currently offering MagForce's NanoTherm Therapy System for the commercial treatment of brain tumors. As one of the academic teaching hospitals of the University of Göttingen, the hospital draws on over 100 years of experience as a successful healthcare and medical service provider.

With two modern, future-oriented hospitals, the subsidiary Hufeland MVZ GmbH with a total of more than 1,300 qualified employees in the Hufeland network offer highly specialized medical services, thus ensuring medical care for patients in Bad Langensalza, Mühlhausen and the surrounding area. Since the opening of the Department of Neurosurgery and Spinal Surgery in July 2017, the range of operations has constantly expanded, and outpatient neurosurgical consultations are also held regularly at Hufeland MVZ GmbH.

"We are very pleased that with the Hufeland Klinikum, another competent center for the treatment of brain tumor patients with our NanoTherm Therapy System will soon be established in Central Germany. PD Dr. Wölfer not only has many years of experience with our therapy but was also instrumental in the further development of the application method, which is now being used at other hospitals. We look forward to continuing our long-standing cooperation with the Hufeland Klinikum," said Dr. Ben Lipps, Chief Executive Officer of MagForce AG and MagForce USA, Inc.

The role of NanoTherm therapy in the treatment of brain tumors

NanoTherm therapy is a relatively new procedure for the focal treatment of solid tumors. Simplified summary: Magnetic nanoparticles are instilled either directly into the tumor or into the resection cavity wall. These particles are then heated by an alternating magnetic field, thereby destroying the cancer cells.

The nanoparticles are tiny particles of iron oxide suspended in water, i.e. very finely distributed, with a diameter of approximately 15 nanometers. One nanometer corresponds to a millionth of a millimeter. As soon as they are applied, the particles agglomerate and remain in the tissue to be treated like an implant. The particles are then made to generate heat in an alternating magnetic field that changes polarity up to 100,000 times per second.

Depending on the therapeutic temperatures reached in the tumor or individual remaining cancer cells in the resection cavity wall and the duration of treatment, the cancer cells are irreparably destroyed as a result, or they become weakened and more sensitive to accompanying radio- or chemotherapy. The type of application of the nanoparticles is decided individually by the treating neurosurgeon.

This new technique makes it possible to fight the tumor from the inside or, after surgical removal of the tumor, to ensure that isolated residual tumor cells in the resection cavity wall - which could trigger recurrences - are fought and destroyed. The surrounding healthy tissue is spared, since the particles remain at the site of application due to their special surface structure.
 

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

Contact:

MagForce AG
Max-Planck-Straße 3, 12489 Berlin
www.magforce.com

Press and investor contact information:
Barbara von Frankenberg
VP Communications & Investor Relations
Phone +49 30 308380-77
bfrankenberg(at)magforce.com

Business Biotechnology / Environment

Related News

  • Logo: MagForce AG

    MagForce AG Successfully Completes Private Placement of New Shares

    Medical device company increases share capital with gross proceeds of approx. EUR 4.7 million
  • Logo: MagForce AG

    MagForce AG and affiliated European clinics support World Brain Tumor Day on 8 June

    At virtual events, patients receive advice on treatment approaches with NanoTherm Therapy
  • Magnetic liquid for NanoTherm® treatment. Credit: MagForce AG

    The aim to provide brain tumor patients with the best care possible

    MagForce hosts practice-oriented application training for the use of the NanoTherm therapy system in treating brain tumors and intends to increase the availability of the therapy
  • MagForce AG installs NanoActivator® at the University Hospital Münster

  • MagForce AG Receives Further Patent Related to NanoTherm® Therapy

    European patent granted for nanoparticle-drug conjugates
  • LinkedInshare0
  • Facebookshare0
  • WhatsAppshare0
  • E-Mail

The development of the Science and Technology Park Berlin Adlershof was and is co-financed by the European Union namely by EFRE. This concerns infrastructure development like construction of technology centres. Furthermore EFRE is used for international projects.

  • © WISTA Management GmbH
  • Legal Notice
  • Privacy Policy
  • Social Media Guide
  • FAQ
  • Contact
  • Press
  • Newsletter
  • RSS
  • International
Member of:
Zukunftsort Adlershof Logo